Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth, GSK Vaccines May Get Sales Boost Under Pilot For Developing Countries

Executive Summary

Pediatric pneumococcal vaccines in development by Wyeth and GlaxoSmithKline could be the first products to benefit from a pilot program designed to create an incentive to develop vaccines that treat the diseases of the developing world

You may also be interested in...



BIO maps incentives for neglected diseases

The Biotechnology Industry Organization highlights incentives for innovation for diseases in developing countries, including Advanced Market Commitments, R&D tax incentives, priority review vouchers, transferable exclusivity, Track II patents and even prizes in the paper released June 18 at the BIO International Convention in San Diego, Calif. Some of the incentives are already being adopted. For example, the FDA Amendments Act includes a mechanism to encourage development of tropical diseases - including AIDS - by offering sponsors a transferable priority review voucher. Additionally, an investigational version of Wyeth's currently marketed Prevnar is an anticipated candidate for a pediatric pneumococcal AMC, as is an investigational vaccine, Streptorix, being developed by GlaxoSmithKline (1"The Pink Sheet," Nov. 26, 2007, p. 24)

BIO maps incentives for neglected diseases

The Biotechnology Industry Organization highlights incentives for innovation for diseases in developing countries, including Advanced Market Commitments, R&D tax incentives, priority review vouchers, transferable exclusivity, Track II patents and even prizes in the paper released June 18 at the BIO International Convention in San Diego, Calif. Some of the incentives are already being adopted. For example, the FDA Amendments Act includes a mechanism to encourage development of tropical diseases - including AIDS - by offering sponsors a transferable priority review voucher. Additionally, an investigational version of Wyeth's currently marketed Prevnar is an anticipated candidate for a pediatric pneumococcal AMC, as is an investigational vaccine, Streptorix, being developed by GlaxoSmithKline (1"The Pink Sheet," Nov. 26, 2007, p. 24)

NIH Public/Private Partner Grants Highlighted At BIO/Gates Forum

The National Institute of Health's initiative to provide grants to public/private partnerships for early-stage research marks one of several collaborative efforts to advance tropical disease and HIV compounds, NIAID Director Anthony Fauci said March 12

Related Content

UsernamePublicRestriction

Register

PS049062

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel